Madhav Seshadri, MD, BA

Assistant Professor

I take care of people with lymphoma and chronic lymphocytic leukemia. I believe in taking an individualized approach to each patient's care. By understanding their values and priorities, together we will arrive at the best treatment plan.

I graduated with honors from Emory University School of Medicine in Atlanta. I completed residency in Internal Medicine and fellowship in Hematology and Oncology at New York Presbyterian Hospital/Weill Cornell Medical Center in New York, where I also served as Chief Fellow. At UCSF I am fortunate to practice at a leading medical center which is at the forefront of cancer care.

Technologies for the diagnosis and treatment of lymphoma and CLL are rapidly evolving, and I will use the latest advancements in providing care for patients. We are also fortunate to have a strong team of specialty consultants, nurse practitioners, nurses, medical technicians, pharmacists, and administrative staff. It would be a privilege to care for you or your family member.

Education
2022 - Chief Fellow, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical Center
2022 - Fellowship, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical Center
2019 - Residency, Internal Medicine, New York-Presbyterian Hospital, Weill Cornell Medical Center
MD, 2016 - , Emory University School of Medicine
BA, 2009 - Neuroscience, Johns Hopkins University
Honors and Awards
  • Research Training Award for Fellows, American Society of Hematology, 2021-2022
  • Abstract Achievement Award, American Society of Hematology, 2021
  • Ann Hoyt Jolley Merit Scholarship, Emory University School of Medicine, 2015-2016
Publications

  1. Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R, Smith TJ, Trapani D, Woodard AB, Cigler T. WBC Growth Factors: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026. PMID: 41740078


  2. Tolu SS, Gribbin C, Chen Z, Seshadri MR, Orlando E, Grenet J, Toor R, Sanjurjo A, Cherng HJ, Sawas A, Phillips A, Shore T, Martin P, Leonard JP, Inghirami G, van Besien K, Pro B, Amengual JE, Ruan J. Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. Leukemia & lymphoma 2025. PMID: 40811484


  3. Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, Seshadri MR, Falade A, Habib A, Ayers AA, Bailey M, Brown A, Bailey N, Patel K, Andreadis CB, Kittai AS, Jacobson C, Palmer J, Forman SJ, Nastoupil L, Budde LE. Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. American journal of hematology 2024. PMID: 39715004


  4. Barrios JP, Seshadri MR, Tison GH. Artificial Intelligence to Complement, Not Replace, Clinical Knowledge: Reading Between the Lines. JACC. CardioOncology 2024. PMID: 38774016


  5. Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB. Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy. European journal of nuclear medicine and molecular imaging 2023. PMID: 37300573


  6. Laurence J, Nuovo G, Racine-Brzostek SE, Seshadri M, Elhadad S, Crowson AN, Mulvey JJ, Harp J, Ahamed J, Magro C. Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. Volume 192 of Issue 9. The American journal of pathology 2022. PMID: 35640675


  7. Seshadri M, Crane GM, Gergis U. Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Volume 15 of Issue 1. Hematology/oncology and stem cell therapy 2022. PMID: 32413419


  8. Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Volume 63 of Issue 4. Leukemia & lymphoma 2021. PMID: 34783281


  9. Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Volume 96 of Issue 10. American journal of hematology 2021. PMID: 34152624


  10. Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Volume 219. Clinical immunology (Orlando, Fla.) 2020. PMID: 32771488


  11. Seshadri M, Qu CK. Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis. Volume 23 of Issue 4. Current opinion in hematology 2016. PMID: 27071022


  12. Attaluri A, Seshadri M, Mirpour S, Wabler M, Marinho T, Furqan M, Zhou H, De Paoli S, Gruettner C, Gilson W, DeWeese T, Garcia M, Ivkov R, Liapi E. Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. Volume 32 of Issue 5. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2016. PMID: 27151045


  13. Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Volume 13 of Issue 3. Cell metabolism 2011. PMID: 21356520